EXAS vs IBRX · rev $2.76B vs rev $51.2M
EXACT Sciences Corporation (EXAS) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
EXAS currently screens at market cap $20.03B. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the EXAS and IBRX stock pages for the full models.
Not investment advice.